Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Relacorilant

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Corcept’s Lifyorli Combo Improves Ovarian Cancer Survival
    Corcept’s Lifyorli Combo Improves Ovarian Cancer Survival

    10 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260410882270/en/Corcept-Presents-Complete-Data-from-Pivotal-ROSELLA-Trial-in-SGO-Late-Breaker-with-Simultaneous-Publication-in-The-Lancet-Lifyorli-Relacorilant-Plus-Nab-Paclitaxel-Improves-Overall-Survival-in-Patients-with-Platinum-Resistant-Ovarian-Cancer

    BUSINESSWIRE
    10 Apr 2026
    Share Share
    Onco360 Named National Pharmacy Partner For LIFYORLI
    Onco360 Named National Pharmacy Partner For LIFYORLI

    26 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/26/3263438/0/en/Onco360-Has-Been-Selected-as-the-National-Pharmacy-Partner-for-LIFYORLI-relacorilant.html

    GLOBENEWSWIRE
    26 Mar 2026
    Share Share
    Corcept shares surge as lead drug gets FDA nod for ovarian Cancer
    Corcept shares surge as lead drug gets FDA nod for ovarian Cancer

    25 Mar 2026

    // PRESS RELEASE

    https://ir.corcept.com/news-releases/news-release-details/fda-approves-corcepts-selective-glucocorticoid-receptor

    PRESS RELEASE
    25 Mar 2026
    Share Share
    Corcept Therap’s Lifyorlitm Receives Approval in Us
    Corcept Therap’s Lifyorlitm Receives Approval in Us

    25 Mar 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220641

    FDA
    25 Mar 2026
    Share Share
    Corcept Submitted Lead Asset For Approval Despite FDA Warning
    Corcept Submitted Lead Asset For Approval Despite FDA Warning

    30 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/corcept-submitted-lead-asset-approval-despite-fda-warning-success-was-unlikely

    FIERCE BIOTECH
    30 Jan 2026
    Share Share
    Corcept's Cancer Drug Cuts Risk Of Death In Ovarian Cancer Trial
    Corcept's Cancer Drug Cuts Risk Of Death In Ovarian Cancer Trial

    23 Jan 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/corcepts-cancer-drug-meets-main-goal-late-stage-trial-2026-01-22/

    REUTERS
    23 Jan 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.